TABLE 2.

Values of nevirapine pharmacokinetic parametersa

Ishak group (no. of patients)Cmin (ng/ml)Cmax (ng/ml)Cdiffb (ng/ml)Cdiffc (ng/ml)AUCτf (μg·h/ml)CL/Fd (liters/h)
1e (19)4,583 (3,351, 6,268)7,117 (5,146, 9,844)1,820 (1,319, 2,511)2,02969 (48, 99)2.9 (2.0, 4.2)
2 (20)6,021 (4,786, 7,574)7,087 (5,679, 8,846)840 (404, 1,746)1,06074.7 (58, 95)2.68 (2.1, 3.4)
3 (9)5,854 (4,337, 7,901)7,262 (5,163, 10,215)1,135 (590, 2,182)1,36775.1 (53, 107)2.66 (1.9, 3.8)
  • a The algorithms used for Cmin (n = 46 [all patients]), Cmax (subset of n = 33), Cdiff (subset of n = 31), Cdiff (subset of n = 33), AUCτ (subset of n = 33), and CL/F (subset of n = 33) were the observed Cmin, the observed Cmax, Cmax minus Cmin, Cmax minus Cmin, the linear trapezoidal method, and 200 mg/AUC, respectively. The subsets represent 33 additional samples drawn at 1, 2, and 4 h after dosing. The data represent the geometric means (95% confidence intervals).

  • b For two of the patients, the Cmax and Cmin were the same value. As a result, these patients had a value of zero (a nonplausible value) for the Cdiff parameter on the log scale. Therefore, n = 31.

  • c The mean value for Cdiff nevirapine (n = 33).

  • d CL/F, clearance.

  • e Two patients were excluded.

  • f Predose sample used as a surrogate for the sample obtained at 12 h.